ACS chemical neuroscience molecule spotlight on saredutant

Research output: Contribution to journalShort survey

Abstract

Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental-health/management/depression/definition/en/ ). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental-health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere, K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13, S69 -S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.

Original languageEnglish (US)
Pages (from-to)653-654
Number of pages2
JournalACS Chemical Neuroscience
Volume1
Issue number10
DOIs
StatePublished - Oct 20 2010

Fingerprint

Major Depressive Disorder
Neurosciences
Molecules
Drug Industry
Pharmaceutical Preparations
2,2-dithiobis(N-(1-adamantyl)methyl)acetamide
Mental Health
Health
Depression
Phase III Clinical Trials
Sleep Initiation and Maintenance Disorders
Anxiety Disorders
Mental Disorders
Population
Weight Gain
Industry
SR 48968
Incidence

Keywords

  • MDD, major depressive disorders
  • Saredutant
  • neurokinin-2 receptor antagonist

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on saredutant. / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 1, No. 10, 20.10.2010, p. 653-654.

Research output: Contribution to journalShort survey

@article{9702596bca7641a5953830e38743382d,
title = "ACS chemical neuroscience molecule spotlight on saredutant",
abstract = "Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4{\%} of the adult population (www.who.int/mental-health/management/depression/definition/en/ ). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental-health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere, K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13, S69 -S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.",
keywords = "MDD, major depressive disorders, Saredutant, neurokinin-2 receptor antagonist",
author = "Hopkins, {Corey R.}",
year = "2010",
month = "10",
day = "20",
doi = "10.1021/cn100061r",
language = "English (US)",
volume = "1",
pages = "653--654",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on saredutant

AU - Hopkins, Corey R.

PY - 2010/10/20

Y1 - 2010/10/20

N2 - Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental-health/management/depression/definition/en/ ). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental-health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere, K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13, S69 -S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.

AB - Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental-health/management/depression/definition/en/ ). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental-health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere, K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13, S69 -S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.

KW - MDD, major depressive disorders

KW - Saredutant

KW - neurokinin-2 receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=77958457259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958457259&partnerID=8YFLogxK

U2 - 10.1021/cn100061r

DO - 10.1021/cn100061r

M3 - Short survey

C2 - 22776916

AN - SCOPUS:77958457259

VL - 1

SP - 653

EP - 654

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 10

ER -